This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

32/100

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or older in the United States. AD presents with symptoms of cognitive impairment that worsen with disease progression, ultimately affecting an individual's functional abilities, independence, and overall health. Historically, treatment has relied on the mitigation of the adverse effects of the disease; however, the recent development of antiamyloid monoclonal antibodies allows for the targeting of pathologic factors that drive the progression of disease. Nuclear medicine has established itself as a useful tool in the evaluation of AD through the use of PET tracers, which target pathologic biomarkers such as amyloid-β and tau proteins, as well as metabolic processes reflective of neurodegenerative damage. Amyloid-β PET imaging and quantification have recently gained interest for their ability to more effectively diagnose AD and identify patients eligible for treatment with new antiamyloid therapies.

What this study adds

Evidence grade: Low

This article explains that amyloid-beta PET imaging can help diagnose Alzheimer disease and identify patients eligible for new anti-amyloid therapies. It is an overview of imaging's role in evaluation and treatment selection, not a study of whether any treatment cures or prevents the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Casper, A., & Bolin, J. (2026). Alzheimer Disease and the Utility of PET. Journal of Nuclear Medicine Technology. https://doi.org/10.2967/jnmt.125.271758

Vancouver

Casper A, Bolin J. Alzheimer Disease and the Utility of PET. Journal of Nuclear Medicine Technology. 2026. doi:10.2967/jnmt.125.271758. PMID: 41667287.

BibTeX

@article{casper2026-41667287,
  author  = {Casper, Alysia and Bolin, Julie},
  title   = {{Alzheimer Disease and the Utility of PET}},
  journal = {Journal of Nuclear Medicine Technology},
  year    = {2026},
  doi     = {10.2967/jnmt.125.271758},
  pmid    = {41667287},
  url     = {https://doi.org/10.2967/jnmt.125.271758}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

AD presents with symptoms of cognitive impairment that worsen with disease progression, ultimately affecting an individual's functional abilities, independence, and overall health.

Why it matters

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 32/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 31 of the 96 points we could judge it on, which is 32 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of Nuclear Medicine Technology)
Journal's citation record	0 / 4	Journal of Nuclear Medicine Technology: journal h-index 51 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.5 citations a year over 2 year(s) since 2026
Impact for its field and year	3 / 6	Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Julie Bolin holds only 3 work(s), too few to judge a track record — left out of this score
Institution's track record	0 / 3	GateWay Community College: institution h-index 11 (OpenAlex)
Multicenter collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41667287)
Free to read	2 / 2	Free to read
Points	31 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 31 of the 96 points we could judge it on is 32 out of 100.
Total	32 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments from nearby years

Also in Treatments

196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →